Organon ($OGN) Hidden Dividend Cut and Debt Prioritization Case

• $OGN investors filed a claim against Organon for misleading statements about its dividend policy and failing to disclose plans to prioritize debt reduction.

• After slashing its quarterly dividend by 70% on May 1, 2025, $OGN dropped over 27% .

• $OGN investors can join this case to be notified about potential recovery.

Case Details:

Between October 31, 2024 and April 30, 2025, Organon repeatedly told investors that maintaining its quarterly dividend was its #1 capital allocation priority. Executives publicly committed to sustaining regular dividend payouts, even after acquiring Dermavant for $500 million in late 2024. CEO Kevin Ali and CFO Matthew Walsh both reassured shareholders that cash flows remained strong and that free cash generation would continue to support dividend payments.

However, Organon failed to disclose that internally, the company had already shifted its focus toward debt reduction due to rising leverage from the Dermavant deal. While publicly highlighting growth drivers like VTAMA and Nexplanon, the company withheld the fact that it was preparing a massive cut to its dividend.

On May 1, 2025, Organon announced it was cutting its dividend from $0.28 to $0.08 per share—a 70% reduction—in order to accelerate debt paydown. Executives admitted they were redirecting nearly $200 million in capital from shareholders to creditors and deprioritizing shareholder returns.

$OGN dropped 27% that day.

Based on these events, $OGN investors filed a claim against Organon and its executives, accusing the company of the following:

• It misled investors by repeatedly stating the dividend was a top priority while planning to cut it behind the scenes.

• It failed to disclose a strategic shift to deleveraging, misleading the market on capital allocation plans.

Considering all the representations, investors believe Organon hid key financial risks and withheld critical information to support its stock price ahead of the cut.